{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:48:38Z","timestamp":1791413318968,"version":"4.3.3"},"reference-count":49,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:00:00Z","timestamp":1470096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI114776"],"award-info":[{"award-number":["AI114776"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The 2014 outbreak of Ebola virus (EBOV) in Western Africa highlighted the need for anti-EBOV therapeutics. Clomiphene is a U.S. Food and Drug Administration (FDA)-approved drug that blocks EBOV entry and infection in cells and significantly protects EBOV-challenged mice. As provided, clomiphene is, approximately, a 60:40 mixture of two stereoisomers, enclomiphene and zuclomiphene. The pharmacokinetic properties of the two isomers vary, but both accumulate in the eye and male reproductive tract, tissues in which EBOV can persist. Here we compared the ability of clomiphene and its isomers to inhibit EBOV using viral-like particle (VLP) entry and transcription\/replication-competent VLP (trVLP) assays. Clomiphene and its isomers inhibited the entry and infection of VLPs and trVLPs with similar potencies. This was demonstrated with VLPs bearing the glycoproteins from three filoviruses (EBOV Mayinga, EBOV Makona, and Marburg virus) and in two cell lines (293T\/17 and Vero E6). Visual problems have been noted in EBOV survivors, and viral RNA has been isolated from semen up to nine months post-infection. Since the clomiphene isomers accumulate in these affected tissues, clomiphene or one of its isomers warrants consideration as an anti-EBOV agent, for example, to potentially help ameliorate symptoms in EBOV survivors.<\/jats:p>","DOI":"10.3390\/v8080206","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T03:47:39Z","timestamp":1470196059000},"page":"206","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications"],"prefix":"10.3390","volume":"8","author":[{"given":"Elizabeth","family":"Nelson","sequence":"first","affiliation":[{"name":"Department of Cell Biology, University of Virginia, Charlottesville, VA 22908, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Barnes","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, University of Virginia, Charlottesville, VA 22908, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Wiehle","sequence":"additional","affiliation":[{"name":"Repros Therapeutics, Inc., The Woodlands, TX 77380, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1584-026X","authenticated-orcid":false,"given":"Gregory","family":"Fontenot","sequence":"additional","affiliation":[{"name":"Repros Therapeutics, Inc., The Woodlands, TX 77380, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5829-6305","authenticated-orcid":false,"given":"Thomas","family":"Hoenen","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Division of Intramural Research, National Institutes of Health, Hamilton, MT 59840, USA"},{"name":"Friedrich-Loeffler-Institut, D-17493, Greifswald-Insel Riems, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0532-996X","authenticated-orcid":false,"given":"Judith","family":"White","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, University of Virginia, Charlottesville, VA 22908, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"de La Vega, M.-A., Stein, D., and Kobinger, G.P. (2015). Ebolavirus Evolution: Past and Present. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005221"},{"key":"ref_2","unstructured":"World Health Organization Ebola Situation Reports. Available online: http:\/\/apps.who.int\/ebola\/ebola-situation-reports."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1500306","article-title":"Persistence of Ebola Virus in Ocular Fluid during Convalescence","volume":"372","author":"Varkey","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1473-3099(15)70152-0","article-title":"Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: A retrospective cohort study","volume":"15","author":"Clark","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","unstructured":"Deen, G.F., Knust, B., Broutet, N., Sesay, F.R., Formenty, P., Ross, C., Thorson, A.E., Massaquoi, T.A., Marrinan, J.E., and Ervin, E. (2015). Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Preliminary Report. N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1509773","article-title":"Molecular Evidence of Sexual Transmission of Ebola Virus","volume":"373","author":"Mate","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"ref_8","unstructured":"Davey, R.T. (2016, January 22\u201325). PREVAIL II: A Randomized Controlled Trial of ZMapp\u2122 in Acute Ebola Virus Infection. Proceddings of Retroviruses and Opportunistic Infections, Boston, MA, USA."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1016\/S2214-109X(14)70341-9","article-title":"Hyperimmune serum from healthy vaccinated individuals for Ebola virus disease?","volume":"2","author":"Almansa","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1073\/pnas.1200409109","article-title":"Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease","volume":"109","author":"Dye","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1126\/science.345.6195.364","article-title":"Ebola drugs still stuck in lab","volume":"345","author":"Enserink","year":"2014","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature14442","article-title":"Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates","volume":"521","author":"Thi","year":"2015","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"Misasi","year":"2016","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"Bornholdt","year":"2016","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20514","DOI":"10.1038\/srep20514","article-title":"Discovery of an antibody for pan-ebolavirus therapy","volume":"6","author":"Furuyama","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Warren, T.K., Wells, J., Panchal, R.G., Stuthman, K.S., Garza, N.L., van Tongeren, S.A., Dong, L., Retterer, C.J., Eaton, B.P., and Pegoraro, G. (2014). Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature.","DOI":"10.1038\/nature13027"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"190ra79","DOI":"10.1126\/scitranslmed.3005471","article-title":"FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection","volume":"5","author":"Johansen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"290ra89","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity","volume":"7","author":"Johansen","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1038\/emi.2014.88","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs","volume":"3","author":"Kouznetsova","year":"2014","journal-title":"Emerg. Microbes Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9932","DOI":"10.1128\/JVI.01337-15","article-title":"Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists","volume":"89","author":"Cheng","year":"2015","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Madrid, P.B., Chopra, S., Manger, I.D., Gilfillan, L., Keepers, T.R., Shurtleff, A.C., Green, C.E., Iyer, L.V., Dilks, H.H., and Davey, R.A. (2013). A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060579"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/humupd\/2.6.483","article-title":"Development, pharmacology and clinical experience with clomiphene citrate","volume":"2","author":"Dickey","year":"1996","journal-title":"Hum. Reprod. Update"},{"key":"ref_26","unstructured":"Hughes, E., Collins, J., and Vandekerckhove, P. (2000). Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea. Cochrane Database Syst. Rev., CD000056."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1016\/j.fertnstert.2010.03.077","article-title":"Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents","volume":"94","author":"Jungheim","year":"2010","journal-title":"Fertil. Steril."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0090-4295(91)80143-U","article-title":"Possible hypothalamic impotencemale counterpart to hypothalamic amenorrhea?","volume":"38","author":"Guay","year":"1991","journal-title":"Urology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shoemaker, C.J., Schornberg, K.L., Delos, S.E., Scully, C., Pajouhesh, H., Olinger, G.G., Johansen, L.M., and White, J.M. (2013). Multiple cationic amphiphiles induce a niemann-pick C phenotype and inhibit ebola virus entry and infection. PLoS ONE, 8.","DOI":"10.1371\/annotation\/76780c06-ac81-48a3-8cce-509da6858fe5"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1128\/JVI.03398-14","article-title":"Ebola Virus and Severe Acute Respiratory Syndrome Coronavirus Display Late Cell Entry Kinetics: Evidence that Transport to NPC1+ Endolysosomes Is a Rate-Defining Step","volume":"89","author":"Mingo","year":"2015","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1128\/JVI.01828-15","article-title":"Ebolavirus Glycoprotein Directs Fusion through NPC1+ Endolysosomes","volume":"90","author":"Simmons","year":"2015","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e01857\u201315","DOI":"10.1128\/mBio.01857-15","article-title":"Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway","volume":"7","author":"Spence","year":"2016","journal-title":"MBio"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e00565\u201315","DOI":"10.1128\/mBio.00565-15","article-title":"Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo","volume":"6","author":"Herbert","year":"2015","journal-title":"MBio"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1095\/biolreprod25.3.667","article-title":"Agonistic and antagonistic effects of clomiphene citrate and its isomers","volume":"25","author":"Clark","year":"1981","journal-title":"Biol. Reprod."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1210\/endo.140.9.7006","article-title":"Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line","volume":"140","author":"Fitzpatrick","year":"1999","journal-title":"Endocrinology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1517\/13543780903405608","article-title":"Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency","volume":"18","author":"Kaminetsky","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0015-0282(16)49574-9","article-title":"Single-dose pharmacokinetics of clomiphene citrate in normal volunteers","volume":"46","author":"Mikkelson","year":"1986","journal-title":"Fertil. Steril."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/hmg\/ddr543","article-title":"Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites","volume":"21","author":"Kerb","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_39","unstructured":"Wiehle, R.D., Fontenot, G.K., Hsu, K., and Podolski, J. (2016). The Isomers of Clomiphene Citrate Have Dissimilar Dispositions Once Ingested: Results of a Mouse ADE Study, Manuscript preparation."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bju.13244","article-title":"Differential effects of isomers of clomiphene citrate on reproductive tissues in male mice","volume":"117","author":"Fontenot","year":"2016","journal-title":"BJU Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/bju.12363","article-title":"Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study","volume":"112","author":"Wiehle","year":"2013","journal-title":"BJU Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10511","DOI":"10.1128\/JVI.01272-14","article-title":"A Novel Life Cycle Modeling System for Ebola Virus Shows a Genome Length-Dependent Role of VP24 in Virus Infectivity","volume":"88","author":"Watt","year":"2014","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Hoenen, T., Watt, A., Mora, A., and Feldmann, H. (2014). Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes. J. Vis. Exp.","DOI":"10.3791\/52381-v"},{"key":"ref_44","unstructured":"GraphPad Software QuickCalcs. Available online: http:\/\/www.graphpad.com\/quickcalcs\/Ecanything1\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0091270008328096","article-title":"Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease","volume":"49","author":"Ghobadi","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Nihal","year":"2008","journal-title":"FASEB J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.fertnstert.2003.07.044","article-title":"Monitoring plasma concentrations to individualize treatment with clomiphene citrate","volume":"81","author":"Lennard","year":"2004","journal-title":"Fertil. Steril."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0015-0282(98)00537-8","article-title":"Serum concentrations of enclomiphene and zuclomiphene across consecutive cycles of clomiphene citrate therapy in anovulatory infertile women","volume":"71","author":"Young","year":"1999","journal-title":"Fertil. Steril."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2125.1989.tb03430.x","article-title":"Pharmacokinetics of intravenous clomiphene isomers","volume":"27","author":"Szutu","year":"1989","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/8\/8\/206\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:27:37Z","timestamp":1760210857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/8\/8\/206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,2]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8]]}},"alternative-id":["v8080206"],"URL":"https:\/\/doi.org\/10.3390\/v8080206","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,2]]}}}